Meta-Analysis of Predictive Value of ERCC1 Protein Expression in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

WEI Shu-zhen,SHI Yi,SONG Yong

DOI: https://doi.org/10.3969/j.issn.1671-5144.2010.06.008

2010-01-01

Journal of Evidence-Based Medicine

Abstract:Objective To examine ERCC1 protein expression and sensitivity to platinum-based chemotherapy in non-small cell lung cancer(NSCLC)patients.Methods We electronically searched the CNKI,WANFANG,PubMed,EMBASE and ASCO proceedings.We also hand-searched some published and unpublished references.Inclusion criteria were NSCLC patients,received platinum-based chemotherapy,evaluation of ERCC1 expression and overall response rate.Meta-analysis was conducted by The Corhrane Collaboration's RevMan 4.2 software.Results We finally identified fourteen studies with 1 086 patients.The number of patients with high ERCC1 protein expression was 524 and the response rate to platinum-based chemotherapy was 28.1%.Patients with negative ERCC1 protein expression were 562 and the response rate to platinum-based chemotherapy was 46.6%.The test for heterogeneity showed that all eligible had heterogeneity(χ2=22.93,P=0.04).The combined odds ratio(OR)was 1.92,with 95% confidence interval of 1.48～2.49.Conclusion Compared to patients with positive ERCC1 protein expression,the patients with negative ERCC1 protein expression in advanced NSCLC were more sensitive to platinum-based chemotherapy.